Jump Financial LLC Acquires Shares of 24,171 Applied Therapeutics, Inc. (NASDAQ:APLT)

Jump Financial LLC acquired a new stake in Applied Therapeutics, Inc. (NASDAQ:APLTFree Report) during the fourth quarter, HoldingsChannel reports. The firm acquired 24,171 shares of the company’s stock, valued at approximately $81,000.

Several other hedge funds also recently added to or reduced their stakes in APLT. Vontobel Holding Ltd. acquired a new position in Applied Therapeutics during the fourth quarter worth approximately $34,000. Commonwealth Equity Services LLC purchased a new position in shares of Applied Therapeutics during the 3rd quarter worth approximately $34,000. Rock Springs Capital Management LP lifted its holdings in Applied Therapeutics by 3.6% in the third quarter. Rock Springs Capital Management LP now owns 808,809 shares of the company’s stock valued at $2,014,000 after acquiring an additional 28,018 shares during the period. Citigroup Inc. acquired a new stake in shares of Applied Therapeutics in the third quarter valued at about $164,000. Finally, Worth Venture Partners LLC acquired a new position in Applied Therapeutics during the third quarter worth $483,000. 98.31% of the stock is currently owned by hedge funds and other institutional investors.

Applied Therapeutics Stock Performance

NASDAQ APLT opened at $4.40 on Friday. The firm has a market capitalization of $502.79 million, a PE ratio of -2.39 and a beta of 1.91. Applied Therapeutics, Inc. has a one year low of $1.18 and a one year high of $9.39. The company has a 50-day simple moving average of $4.99 and a 200-day simple moving average of $4.09.

Applied Therapeutics (NASDAQ:APLTGet Free Report) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.18). The company had revenue of ($0.67) million for the quarter.

Insider Buying and Selling at Applied Therapeutics

In other Applied Therapeutics news, insider Riccardo Perfetti sold 110,804 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $5.39, for a total value of $597,233.56. Following the completion of the sale, the insider now directly owns 1,031,537 shares of the company’s stock, valued at approximately $5,559,984.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Riccardo Perfetti sold 110,804 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $5.39, for a total value of $597,233.56. Following the completion of the sale, the insider now owns 1,031,537 shares in the company, valued at $5,559,984.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Leslie D. Funtleyder sold 28,727 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $5.39, for a total value of $154,838.53. Following the completion of the transaction, the chief financial officer now owns 308,421 shares in the company, valued at approximately $1,662,389.19. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 458,104 shares of company stock valued at $2,469,181. Company insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on APLT. UBS Group boosted their target price on shares of Applied Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Citigroup boosted their target price on Applied Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Leerink Partnrs restated an “outperform” rating on shares of Applied Therapeutics in a report on Thursday, February 22nd. SVB Leerink initiated coverage on shares of Applied Therapeutics in a research report on Thursday, February 22nd. They set an “outperform” rating and a $12.00 price target on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $12.00 price objective on shares of Applied Therapeutics in a research report on Thursday, April 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $11.00.

Get Our Latest Research Report on APLT

Applied Therapeutics Company Profile

(Free Report)

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

Read More

Want to see what other hedge funds are holding APLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Therapeutics, Inc. (NASDAQ:APLTFree Report).

Institutional Ownership by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.